BioPharma Resources

Drug Trial Radar · NCT05059522

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

AVELUMAB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM PFIZER-SPONSORED AVELUMAB CLINICAL STUDIES.

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

77

Actual

Start

Sep 29, 2021

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Sep 28, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Master Protocol for Avelumab Continuation Sub-Studies is to provide continued treatment access, safety follow-up, and when applicable, overall survival follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer-sponsored Avelumab parent studies.

Conditions

  • Advanced Malignancies
  • NSCLC
  • Ovarian Cancer
  • Urothelial Cancer
  • Solid Tumors

Interventions

  • AvelumabDrug

    oral

  • LorlatanibDrug

    oral

  • TalazoparibDrug

    oral

  • PemetrexedDrug

    IV (intravenous) infusion

  • AxitinibDrug

    oral

  • CMP 001Drug

    IT (intratumoral) or SC (subcutaneous)

  • UtomilumabDrug

    IV infusion

  • PF04518600Drug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events leading to permanent discontinuation of study interventionTime frame: Baseline up to approximately 5 years
  2. Number serious adverse events reported for all participantsTime frame: Baseline up to approximately 5 years

Locations

71 sites in 19 countries. Site status is shown where the registry gives one.

  • Highlands Oncology Group, PA

    Fayetteville, Arkansas

  • Highlands Oncology Group, PA

    Rogers, Arkansas

  • Highlands Oncology Group, PA

    Springdale, Arkansas

  • The Regents of the University of California

    Los Angeles, California

  • UCLA Hematology/Oncology

    Los Angeles, California

  • Moffitt Cancer Center

    Tampa, Florida

  • MSK Basking Ridge

    Basking Ridge, New Jersey

  • MSK Monmouth

    Middletown, New Jersey

  • MSK Bergen

    Montvale, New Jersey

  • MSK Commack

    Commack, New York

  • MSK Westchester

    Harrison, New York

  • Memorial Sloan Kettering Cancer Center (IDS Pharmacy)

    Long Island City, New York

  • Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).

    New York, New York

  • Memorial Sloan Kettering Cancer Center 53rd street.

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • MSK Nassau

    Uniondale, New York

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania

  • The Trustees of the University of Pennsylvania, Clinical Research (OCR)

    Philadelphia, Pennsylvania

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Fred Hutchinson Cancer Center

    Seattle, Washington

  • Macquarie University

    North Ryde, New South Wales, Australia

  • Mater Hospital Sydney

    Wollstonecraft, New South Wales, Australia

  • Melanoma Institute Australia

    Wollstonecraft, New South Wales, Australia

  • The Prince Charles Hospital

    Chermside, Queensland, Australia

  • Grand Hôpital de Charleroi

    Gilly, Belgium

  • UZ Gent

    Ghent, Oost-vlaanderen, Belgium

  • Cross Cancer Institute

    Edmonton, Alberta, Canada

  • Kingston Health Sciences Centre-Kingston General Hospital Site

    Kingston, Ontario, Canada

  • Aalborg Universitetshospital, Syd

    Aalborg, North Denmark, Denmark

  • Institut de Cancérologie de Lorraine Alexis Vautrin

    Vandœuvre-lès-Nancy, Lorraine, France

  • Országos Onkológiai Intézet

    Budapest, Hungary

  • Rabin Medical Center

    Petah Tikva, Central District, Israel

  • Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I - G.M. Lancisi - G. Salesi

    Ancona, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    Milan, Lombardy, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    Milan, Milano, Italy

  • IRCCS Istituto Clinico Humanitas

    Rozzano, Milano, Italy

  • National Hospital Organization Kyushu Cancer Center

    Fukuoka, Japan

  • Oita University Hospital

    Yufu, Oita Prefecture, Japan

  • National Cancer Center Hospital

    Chuo-ku, Tokyo, Japan

  • Japanese Foundation for Cancer Research

    Koto, Tokyo, Japan

Showing 40 of 71 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.